紫杉醇联合卡铂化疗同期调强适形放疗在老年晚期宫颈癌患者中的应用

目的探讨采用紫杉醇联合卡铂化疗同期调强适形放疗治疗老年晚期宫颈癌的临床效果。方法选取2107年2月至2018年7月本院所收治老年晚期宫颈癌患者82例,按照治疗方案的不同分为观察组(紫杉醇联合卡铂化疗+同期调强适形放疗)和对照组(单纯常规化疗方案的患者),对两组患者的临床治疗效果、不良反应发生情况进行评估分析。结果观察组患者总治疗有效率高于对照组(92.7%和75.6%,χ2=4.479,P=0.034);观察组患者的肿瘤转移率低于对照组(2.4%和14.6%,χ2=3.905,P=0.048);观察组患者Ⅲ级以上胃肠不良反应发生率低于对照组(8.1%和45.5%,χ2=12.736,P=0.000)。结论采用紫杉醇联合卡铂同期调强适形放疗治疗老年晚期宫颈癌,可有效增强对肿瘤组织的控制效果,并有助于降低治疗期间患者不良反应的发生风险,有利于减轻患者痛苦,保证临床治疗的顺利进行。

Clinical evaluation of Paclitaxel and Carboplatin combination chemotherapy plus intensity-modulated radiotherapy for elderly patients with advanced cervical cancer

Objective To investigate the clinical effects of Paclitaxel and Carboplatin combination chemotherapy with concurrent intensity-modulated radiotherapy for elderly patients with advanced cervical cancer.Methods From February 2107 to July 2018,82 patients with advanced cervical cancer were enrolled from our hospital.According to the treatment plan,they were divided into the observation group(patients with Paclitaxel/Carboplatin chemotherapy+concurrent intensity-modulated radiation therapy)and the control group(patients with conventional chemotherapy).Clinical effects and the occurrence of toxic and side effects were evaluated and analyzed for the two groups.Results The overall rate of effectiveness for the observation group was 92.7%,which was higher than that for the control group(75.6%),and the difference was statistically significant(χ2=4.479,P=0.034).The tumor metastasis rate was lower in the observation group than in the control group(2.4%vs.14.6%,χ2=3.905,P=0.048).The incidence of gastrointestinal side effects>gradeⅢwas lower in the observation group than in the control group(8.1%vs.45.5%,χ2=12.736,P=0.000).Conclusions Paclitaxel and Carboplatin plus intensity-modulated radiotherapy for elderly patients with advanced cervical cancer can help keep tumor size under control,reduce the risk of toxic and side effects during treatment,alleviate patient suffering,and ensure a smooth treatment experience.